These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Plasma (1 → 3)-β-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis. Gianella S; Letendre SL; Iudicello J; Franklin D; Gaufin T; Zhang Y; Porrachia M; Vargas-Meneses M; Ellis RJ; Finkelman M; Hoenigl M J Neurovirol; 2019 Dec; 25(6):837-843. PubMed ID: 31297727 [TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study. Rasmussen LJ; Knudsen A; Katzenstein TL; Gerstoft J; Obel N; Jørgensen NR; Kronborg G; Benfield T; Kjaer A; Eugen-Olsen J; Lebech AM HIV Med; 2016 May; 17(5):350-7. PubMed ID: 26365671 [TBL] [Abstract][Full Text] [Related]
4. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. Tenorio AR; Zheng Y; Bosch RJ; Krishnan S; Rodriguez B; Hunt PW; Plants J; Seth A; Wilson CC; Deeks SG; Lederman MM; Landay AL J Infect Dis; 2014 Oct; 210(8):1248-59. PubMed ID: 24795473 [TBL] [Abstract][Full Text] [Related]
5. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. Sereti I; Krebs SJ; Phanuphak N; Fletcher JL; Slike B; Pinyakorn S; O'Connell RJ; Rupert A; Chomont N; Valcour V; Kim JH; Robb ML; Michael NL; Douek DC; Ananworanich J; Utay NS; Clin Infect Dis; 2017 Jan; 64(2):124-131. PubMed ID: 27737952 [TBL] [Abstract][Full Text] [Related]
6. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS. Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750 [TBL] [Abstract][Full Text] [Related]
7. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. Lawn SD; Myer L; Bangani N; Vogt M; Wood R BMC Infect Dis; 2007 May; 7():41. PubMed ID: 17509133 [TBL] [Abstract][Full Text] [Related]
8. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678 [TBL] [Abstract][Full Text] [Related]
9. Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity. Burcsár S; Toldi G; Kovács L; Szalay B; Vásárhelyi B; Balog A Biomarkers; 2021 Jul; 26(5):443-449. PubMed ID: 33825610 [TBL] [Abstract][Full Text] [Related]
10. Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study. van den Berg VJ; Bouwens E; Umans VAWM; de Maat M; Manintveld OC; Caliskan K; Constantinescu AA; Mouthaan H; Cornel JH; Baart S; Akkerhuis KM; Boersma E; Kardys I Thromb Haemost; 2019 Dec; 119(12):1947-1955. PubMed ID: 31659734 [TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study. Fourie CM; Van Rooyen JM; Kruger A; Olsen MH; Eugen-Olsen J; Schutte R; Schutte AE Inflammation; 2012 Feb; 35(1):221-9. PubMed ID: 21384094 [TBL] [Abstract][Full Text] [Related]
12. Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study. Langkilde A; Petersen J; Klausen HH; Henriksen JH; Eugen-Olsen J; Andersen O PLoS One; 2012; 7(12):e51698. PubMed ID: 23251607 [TBL] [Abstract][Full Text] [Related]
13. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F Crit Care; 2011; 15(1):R63. PubMed ID: 21324198 [TBL] [Abstract][Full Text] [Related]
14. Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis. Drechsler C; Hayek SS; Wei C; Sever S; Genser B; Krane V; Meinitzer A; März W; Wanner C; Reiser J Clin J Am Soc Nephrol; 2017 Aug; 12(8):1265-1273. PubMed ID: 28495863 [TBL] [Abstract][Full Text] [Related]